CMMB (Chemomab Therapeutics Ltd. American Depositary Share)
Insider Trading Activity
Every open-market purchase and sale reported by CMMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Neil Harris Cohen | Director | Sell | — | — |
| 2026-06-01 | George Adi Mor | Chief Executive Officer | MIXED | — | — |
| 2023-07-05 | Nissim Darvish | Director | A | — | — |
| 2023-06-20 | Jill M. Quigley | Director | A | — | — |
| 2023-06-16 | Sigal Fatal | Chief Financial Officer | A | — | — |
| 2023-03-23 | Claude Nicaise | Director | A | — | — |
| 2023-03-23 | Alan Charles Moses | Director | A | — | — |
| 2023-03-23 | Neil Harris Cohen | Director | A | — | — |
| 2023-03-23 | Nissim Darvish | Director | A | — | — |
| 2023-01-05 | George Adi Mor | Chief Scientific Officer | Sell | — | — |
| 2023-01-05 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | Sell | — | — |
| 2022-11-18 | Neil Harris Cohen | Director | Sell | — | — |
| 2022-11-17 | George Adi Mor | Chief Scientific Officer | Sell | — | — |
| 2022-06-21 | Donald Marvin | Executive VP, CFO & COO | Buy | — | — |
| 2022-05-25 | Joel Michael Maryles | Director | Buy | — | — |
| 2022-05-19 | Neil Harris Cohen | Director | Buy | — | — |
| 2022-03-21 | Donald Marvin | Executive VP, CFO & COO | Buy | — | — |
| 2022-03-21 | Joel Michael Maryles | Director | Buy | — | — |
| 2022-03-15 | Dale R Pfost | Chief Executive Officer | Buy | — | — |
| 2022-03-15 | Neil Harris Cohen | Director | Buy | — | — |
| 2022-03-14 | Nissim Darvish | Director | Buy | — | — |
| 2022-03-09 | Claude Nicaise | Director | A | — | — |
| 2022-03-09 | Alan Charles Moses | Director | A | — | — |
| 2022-03-09 | Nissim Darvish | Director | A | — | — |
| 2022-03-09 | Neil Harris Cohen | Director | A | — | — |
| 2022-03-09 | Joel Michael Maryles | Director | A | — | — |
| 2021-12-08 | Neil Harris Cohen | Director | Buy | — | — |
| 2021-05-10 | Sigal Fatal | Chief Financial Officer | A | — | — |
| 2021-04-21 | Alan Charles Moses | Director | A | — | — |
| 2021-04-21 | Joel Michael Maryles | Director | A | — | — |
| 2021-04-21 | STEPHEN P SQUINTO | Director | A | — | — |
| 2021-04-21 | Nissim Darvish | Director | A | — | — |
| 2021-04-21 | Claude Nicaise | Director | A | — | — |
| 2021-04-21 | Neil Harris Cohen | Director | A | — | — |
| 2021-03-26 | Neil Harris Cohen | Director | Buy | — | — |
| 2021-03-18 | PETER THIEL | 10%+ Owner | Buy | — | — |
| 2021-03-18 | OrbiMed Israel GP Ltd. | 10%+ Owner | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 644,544 | — |
| — | 10%+ Owner | 577,950 | — |
| — | 10%+ Owner | 277,127 | — |
| — | Chief Executive Officer | 94,499 | — |
| — | Director | 34,000 | — |
| — | Director | 11,984 | — |
| — | Chief Financial Officer | 1,302 | — |
| — | Chief Executive Officer | 450 | — |
| — | Executive VP, CFO & COO | 438 | — |
| — | Director | 358 | — |
| — | Director | 300 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMMB quote page; the site-wide leaderboard is on the insider transactions hub.